Dossier assessment

Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A20-69
Last updated

Report documents

  1. Extract of dossier assessment

    Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 541 kB, EN, not accessible
  2. Dossier assessment

    Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 586 kB, DE, not accessible

Dossier assessment

Indication:

Adults with asthma not adequately controlled with a maintenance combination of a LABA and a high dose of an ICS who experienced one or more asthma exacerbations in the previous year

Result of dossier assessment:

No statistically significant differences in any outcome; added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2021-02-04: A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A20-69
Commission
Commission awarded on 07.08.2020 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Airways and respiratory system

Connected Projects

  1. Addendum

    Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Addendum to Commission A20-69

    Project no.
    A20-125
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form